newsfilter
← Latest News
GlobeNewswire·

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

  • JADE101 Phase 1 healthy volunteer trial is ongoing with biomarker-rich interim data expected in the first half of 2026
  • Phase 2 clinical trial for JADE101 in patients with IgA nephropathy is expected to begin mid-2026 with preliminary data anticipated in 2027
  • JADE201 is expected to advance into a first-in-human study for rheumatoid arthritis in the second quarter of 2026 with interim data anticipated in 2027
  • Third development candidate JADE301 is nominated for preclinical development with Phase 1 expected to commence in the first half of 2027
  • Company expects approximately $336 million in cash, cash equivalents, & investments as of December 31, 2025 to provide runway into the first half of 2028
  • Jade Biosciences will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 11:15 a.m. PT
  • JADE101 is an investigational anti-APRIL monoclonal antibody designed to treat IgA nephropathy through selective inhibition & half-life extension
  • JADE201 is a half-life extended, afucosylated anti-BAFF receptor antibody designed to enable less frequent subcutaneous dosing & deeper B-cell depletion
  • Jade plans to disclose further details on the undisclosed JADE301 program in the second half of 2026